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Clinical and pathologic characteristics of dilated
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Clinical and pathologic characteristics of dilated cardiomyopa-
thy in hemodialysis patients.
Background. Some dialysis patients have impaired left ven-
tricular (LV) function without coronary artery disease. The
pathologic changes and prognoses of these patients have not
been well described.
Methods. We performed LV endomyocardial biopsies on 40
hemodialysis patients with dilated cardiomyopathy (DCM; an
ejection fraction <50% and a left ventricular end-diastolic vol-
ume index >90 mL/m2 without coronary artery disease), and
on 50 nondialysis patients with idiopathic DCM as the control
group. Following LV biopsies, the patients were followed-up for
a mean of 3.1 ± 2.3 years.
Results. The pathologic characteristics of the dialysis group
were severe myocyte hypertrophy (the mean myocyte diameter
across the nucleus: 37.6 ± 10.5 lm vs. 25.6 ± 7.7 lm, P = 0.001),
myocyte disarray (30%), and extensive fibrosis (the mean per-
cent area of left ventricular fibrosis: 22.3 ± 18.4% vs. 21.3 ±
14.6%, P = NS). These pathologic characteristics resembled the
dilated phase of hypertrophic cardiomyopathy. In the dialysis
group, a high percent area of LV fibrosis was the only signif-
icant predictor of cardiac death by multivariate analysis (P =
0.02). The 3-year cumulative event-free survival rate for car-
diac death in dialysis patients with severe fibrosis (more than
30%) was 42%, while that for patients without severe fibrosis
was 82% (P = 0.03).
Conclusion. The pathologic characteristics of the heart in
dialysis patients with DCM are interstitial fibrosis and severe
myocyte hypertrophy with occasional disarray. The extent of LV
fibrosis is a strong predictor of cardiac death. Careful follow-
up and treatment are necessary for dialysis patients with a high
percent area of LV fibrosis.
Left ventricular dysfunction and congestive heart fail-
ure (CHF) are common complications of patients on
chronic dialysis, and account for almost 40% of deaths in
this population [1]. Some dialysis patients have impaired
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left ventricular (LV) function without significant coro-
nary artery disease, which occurs in dilated cardiomyopa-
thy (DCM), but the clinical and pathologic characteristics
of these patients have not been well described. We inves-
tigated the clinicopathologic characteristics of this group
of patients in the present study.
METHODS
Patients
From April 1994 to October 2002, a total of 12,943 car-
diac catheterizations were performed at our institution.
Among these, we performed initial coronary angiography
and left ventriculography in 286 hemodialysis patients to
investigate coronary artery disease (CAD) or impaired
LV function. Of the 286 hemodialysis patients, 198 had
CAD and 88 did not. Among the 88 hemodialysis patients
without CAD, 40 had impaired LV function and LV dilata-
tion (an ejection fraction<50% and a left ventricular end-
diastolic volume index >90 mL/m2, respectively) without
severe valvular disease. These patients were diagnosed as
dilated cardiomyopathy and underwent LV biopsy (the
dialysis group). During the same period, 50 patients with a
diagnosis of idiopathic dilated cardiomyopathy who were
not on dialysis underwent LV biopsy (the control group).
The etiology of impaired LV function and LV dilatation in
this latter group of patients was unknown. Based on previ-
ous medical records, including echocardiographic studies,
it was ascertained that none of the 90 patients were in the
dilated phase of hypertrophic cardiomyopathy. Following
LV biopsy, the clinical status was prospectively followed-
up until the last contact. Written, informed consent was
obtained from all 90 patients.
Echocardiography
Standard two-dimensional (2-D), M-mode echocardio-
graphy images, and Doppler echocardiography of mitral
flow were obtained before hemodynamic measurement
and left ventriculography. Wall thickness and LV diame-
ter were derived from M-mode echocardiograms accord-
ing to the American Society of Echocardiography [2].
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Table 1. Patient characteristics
Dialysis patients
Fibrosis area
Control patients All patients <30% ≥30% P valuea
N 50 40 28 (70%) 12 (30%)
Male 44 (88%) 30 (75%) 20 (71%) 10 (83%) ns
Age 56 ± 12 56 ± 11 56 ± 12 56 ± 7 ns
NYHA class
I 4 (8%) 0 (0%) 0 (0%) 0 (0%) ns
II 20 (40%) 11 (28%) 8 (29%) 3 (25%) ns
III 18 (36%) 19 (48%) 14 (50%) 5 (42%) ns
IV 8 (16%) 10 (25%) 6 (21%) 4 (33%) ns
CTR% 57 ± 5 55 ± 6 56 ± 6 54 ± 5 ns
Hypertension 17 (34%) 25 (63%)b 19 (68%) 6 (50%) ns
Diabetes mellitus 8 (16%) 8 (20%) 4 (14%) 4 (33%) ns
Hemoglobin g/dL 14.7 ± 2.1 10.5 ± 1.7b 10.3 ± 1.6 10.8 ± 2.1 ns
Ca mg/dL 8.9 ± 0.6 9.1 ± 0.8 9.1 ± 0.8 8.9 ± 0.6 ns
P mg/dL 3.4 ± 0.5 5.3 ± 1.8b 5.5 ± 2.0 4.6 ± 0.9 ns
ACE-I/ARB 44 (88%) 22 (55%)b 18 (64%) 4 (33%) ns
Beta blocker 20 (40%) 9 (23%) 7 (25%) 2 (17%) ns
Dialysis duration – 8.3 ± 6.5 7.1 ± 6.2 11.1 ± 6.6 ns
Abbreviations are: NYHA class, New York Heart Association functional classification; CTR, cardiothoracic ratio; Ca, calcium; P, phosphorus; ACE, angiotensin-
converting enzyme inhibitor; ARB, angiotensin receptor antagonist.
aP value shows the fibrosis area <30% group vs. the fibrosis ≥30% group.
bP value < 0.05; P value shows the control group vs. the dialysis group.
Doppler recordings of mitral inflow were performed in
the apical 4-chamber view to determine the early dias-
tolic peak velocity, late atrial diastolic peak velocity, and
deceleration time [3].
Measurement of hemodynamics and left
ventriculography
In the dialysis group, measurement of hemodynam-
ics and left ventriculography was performed between
hemodialysis sessions. Before coronary angiography, the
pulmonary capillary wedge pressure and LV end-diastolic
pressure were measured with a fluid-filled catheter.
Cardiac output was determined by the thermo-dilution
method as the mean value of at least 3 measurements.
Quantitative ventriculography was performed in 2 stan-
dard views (30◦ right anterior oblique and 45◦ left, 20◦
cranial oblique) by injecting 35 mL of contrast medium
into the left ventricle through a 6-French pigtail catheter
at a speed of 12 mL/s.
Quantitative morphometry
LV endomyocardial biopsy specimens were obtained
from at least 3 sites on the LV lateral wall using Cook flexi-
ble biopsy forceps (Cook Incorporated, Bloomington, IN,
USA). The myocardial specimens were immediately fixed
in 10% buffered formalin, processed through a graded
series of methanol and xylene solutions, embedded in
paraffin, and finally cut into serial sections that were 3 lm
thick (6 lm for Congo red staining). The 3-lm sections
were then stained with hematoxylin-eosin (HE), Azan-
Mallory (AZ), and elastica van Gieson stains. We used
Azan-Mallory staining to identify the extent of fibrosis.
The area of fibrosis, which was blue on trichrome staining,
was readily distinguished from viable myocardium, which
stained pink. The extent of fibrosis on each section was de-
termined by computer image analysis using Scion image
software (Scion Corporation, Frederick, MD, USA). In
each biopsy specimen, the mean myocyte diameter across
the nucleus was determined as the mean of 50 measure-
ments from longitudinally sectioned myocytes, excluding
tissue immediately beneath the endomyocardial layer on
HE-stained sections at 400× magnification.
Statistical analysis
Continuous data were expressed as the mean ± stan-
dard deviation. Intergroup comparisons of continuous
variables were done with Student unpaired t test. Cate-
gorical data were presented as frequencies and analyzed
using the chi-square test. If the expected number was less
than 5, Fisher exact test was used. Event-free survival
curves were constructed using Kaplan-Meier product-
limit estimates, and were compared using the log-rank
test. The Cox hazard model was applied for multivariate
analysis. All statistical analyses were conducted using Stat
View 5.0 (SAS Institute, Inc., Cary, NC, USA), and P val-
ues less than 0.05 were considered statistically significant.
RESULTS
Patient characteristics
We studied 40 dialysis and 50 control patients with
DCM (Table 1). In the dialysis group, the average du-
ration of dialysis was 8.3 ± 6.5 years, and the causes of
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Table 2. Hemodynamic data
Dialysis patients
Fibrosis area
Control patients All patients <30% ≥30% P valuea
N 50 40 28 (70%) 12 (30%)
Echocardigraphic findings
LVDd mm 63 ± 5 59 ± 7b 58 ± 6 62 ± 5 ns
LVDs mm 55 ± 6 50 ± 8b 48 ± 8 54 ± 6 ns
FS % 15 ± 13 16 ± 8 17 ± 8 13 ± 7 ns
IVST mm 10 ± 3 12 ± 3b 11 ± 3 12 ± 4 ns
LVPWT mm 10 ± 2 12 ± 3b 12 ± 3 11 ± 1 ns
E/A 1.2 ± 0.7 1.1 ± 0.6 1.1 ± 0.7 1.0 ± 0.4 ns
Dec time msec 211 ± 103 163 ± 47 163 ± 59 162 ± 23 ns
Hemodynamic findings
PCWP mm Hg 12 ± 8 11 ± 6 11 ± 6 10 ± 5 ns
Cardiac index L/min/m2 2.8 ± 8 3.3 ± 0.8b 3.3 ± 0.7 3.3 ± 0.8 ns
LVEDP mm Hg 13 ± 8 16 ± 8 15 ± 7 18 ± 9 ns
EDVI mL/m2 123 ± 32 124 ± 34 120 ± 30 135 ± 53 ns
ESVI mL/m2 82 ± 30 83 ± 48 79 ± 31 94 ± 57 ns
EF % 34 ± 12 35 ± 18 35 ± 11 38 ± 12 ns
Abbreviations are: LVDd, left ventricular end-diastolic diameter; LVDs, left ventricular end-systolic diameter; FS, fractional shortening; IVST, interventricular
septal thickness; LVPWT, left ventricular posterior wall thickness; E/A, early diastolic peak velocity/late artrial diastolic peak velocity; Dec time; deceleration time;
PCWP, pulmonary capillary wedge pressure; LVEDP, left ventricular end-diastolic pressure; EDVI, left ventricular end-diastolic volume index; ESVI, left ventricular
end-systolic volume index; EF, ejection fraction.
aP value shows the fibrosis area <30% group vs. the fibrosis area ≥30% group.
bP value < 0.05; P value shows the control group vs. the dialysis group.
renal failure included diabetes mellitus (N = 8), chronic
glomerulonephritis (N = 17), hypertension (N = 6), poly-
cystic kidney disease (N = 4), renal cell carcinoma (N =
2), gout (N = 2), and eclampsia (N = 1). The mean car-
diothoracic ratio (CTR) was 55 ± 6%, and the New York
Heart Association (NYHA) functional classification was
class III in 48% and class IV in 25%. The prevalence
of hypertension was significantly higher, and the use of
angiotensin-converting enzyme inhibitors or angiotensin
receptor antagonists was significantly lower than the con-
trol group. In the serologic data, the average hemoglobin
level was significantly lower than the control group, and
the average phosphate level was significantly higher than
the control group.
Echocardiographic data
In the dialysis group, the mean LV end-diastolic diam-
eter and mean LV end-systolic diameter were 59 ± 7 mm
and 50 ± 8 mm, respectively, and the interventricular
septal thickness and left ventricular posterior wall thick-
ness were both 12 ± 3 mm in parasternal long axis view
(Table 2). The LV diameters were statistically shorter,
and the wall thicknesses were statistically thicker than
the control group. Mean levels of early diastolic peak ve-
locity/late atrial diastolic peak velocity (E/A) and mitral
inflow deceleration time were similar between the dialy-
sis and control groups.
Hemodynamic measurements
Mean left ventricular end-diastolic pressure was 16 ±
8 mm Hg in the dialysis group. The left ventricular
end-diastolic volume index (EDVI) and end-systolic vol-
ume index (ESVI) were measured by 30◦ right ante-
rior oblique ventriculography; mean EDVI was 124 ±
34 mL/m2 and mean ESVI was 83 ± 48 mL/m2, and the
mean ejection fraction (EF) was 35 ± 10% in the dialysis
group (Table 2). There were no statistical differences be-
tween the 2 groups. However, cardiac index in the dialysis
group was significantly higher than the control group.
Pathologic findings
Representative histologic findings in a 71-year-old man
(hemodialysis duration: 2.8 years) with diffuse LV hy-
pokinesis (EF = 22%) and LV dilatation (LVEDVI =
193 mL/m2) are shown in Figure 1. There were severely
hypertrophic and bizarre myocytes, as well as intersti-
tial fibrosis, and fibrous tissue surrounds each myocyte
(Fig. 1A and B). Figure 2A shows hypertrophic and
bizarrely shaped myocytes with irregular, enlarged nu-
clei. Quantitative morphometric analysis of the 40 dialysis
patients showed that the mean myocyte diameter across
the nucleus was 37.6 ± 10.5 lm. It was significantly bigger
than the control group (25.6 ± 7.7 lm; P ≤ 0.001) (Fig. 2A
and B). Twelve patients on dialysis (30%) had myocytes
showing similar disarray compared to one patient (2%)
in the control group (Fig. 2C). Figure 4A shows the dis-
tribution of myocyte hypertrophy. Forty-five percent of
the patients with dialysis had severely hypertrophic my-
ocytes (mean myocyte diameter: ≥40 lm) compared to
8% of patients in the control group.
The mean percent area of LV fibrosis was 22.3 ± 18.4%
in the dialysis group and 21.3 ± 14.6% in the control
336 Aoki et al: Cardiomyopathy in dialysis patients
Fig. 1. Representative case: a 71-year-old male patient with heart failure on dialysis for 2.8 years. Hypertrophic and bizarrely shaped myocytes (HE
stain, 400×) (A). Fibrous tissue surrounds each myocyte (AZ stain, 400×) (B). C. Left ventriculography at end diastole: LVEDVI = 193 mL/m2
(30◦ right anterior oblique) (C). Left ventriculography at end systole: EF = 22% (30◦ right anterior oblique) (D).
group. This was not statistically different between the
2 groups. As demonstrated in Figure 4B, the area of fibro-
sis shows a wide distribution. Some patients had severe
fibrosis (Fig. 3A), while some had less prominent fibrosis
(Fig. 3B). Figure 3A shows a typical case of extensive in-
terstitial fibrosis (replacement fibrosis and fibrous tissue
surrounds each myocyte).
Clinical outcome
The mean follow-up period was 3.1 ± 2.3 years. In the
dialysis group, 16 patients died (40%), and cardiac death
occurred in 10 patients (25%). The causes of death were
CHF (N = 7), cerebrovascular disease (N = 3), ventric-
ular arrhythmia (N = 2), infection (N = 2), cancer (N =
1), and sudden death (N = 1). In the control group, 3 pa-
tients died (6%), and cardiac death occurred in 2 pa-
tients (4%). The causes of death were CHF (N = 2) and
leukemia (N = 1). The 3-year event-free cumulative sur-
vival rate for cardiac death was 67% in the dialysis group
and 97% in the control group.
Relationship between pathologic findings
and clinical outcome
The 3-year event-free cumulative survival rate for car-
diac death was 42% in the dialysis group with 30% or
more fibrosis, whereas it was 82% in the dialysis group
that had less than 30% fibrosis. Cumulative survival
curves for the cardiac death group stratified by the extent
of fibrosis are shown in Figure 5. The dialysis group with
30% or more fibrosis had a significantly worse survival
compared with the control group and the dialysis group
that had less than 30% fibrosis, suggesting that dialysis
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Fig. 2. Hypertrophic and bizarrely shaped myocytes with irregular enlarged nuclei. A 68-year-old male patient on dialysis for 7.3 years (HE stain,
400×) (A). A 39-year-old male patient not on dialysis (HE stain, 400×) (B). A 45-year-old female patient on dialysis for 1.9 years (C). Myocytes
show disarray (HE stain, 400×)
Fig. 3. A 56-year-old male patient on dialysis for 7.1 years (A). Widespread fibrosis is present, and interstitial fibrosis surrounds each myocyte (AZ
stain, 400×). This patient died of ventricular arrhythmia 1.1 years after biopsy. A 56-year-old male patient on dialysis for 6.8 years (B). Only a little
interstitial fibrosis is present (AZ stain, 400×). This patient had no cardiac events during 3.8 years of follow-up.
patients with severe fibrosis was related to a poor prog-
nosis. However, when patient characteristics and hemo-
dynamic data were compared, no differences were noted
between the severe fibrosis group and the less severe fi-
brosis group (Tables 1 and 2). Table 3 shows the result of
multivariate analysis of the predictors of cardiac death.
The percent area of LV fibrosis was the only independent
predictor of the prognosis.
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DISCUSSION
This study showed that the pathologic characteristics of
the left ventricle in dialysis patients with DCM were simi-
lar to the findings in the dilated phase of hypertrophic car-
diomyopathy, which are severely hypertrophic myocytes
and widespread interstitial fibrosis, sometimes with my-
ocyte disarray. The mean diameter of cardiac myocytes in
our dialysis patients with DCM was 37.6 ± 10.5 lm, which
is larger than that seen in the normal heart (18 lm), hy-
pertension (24 ± 33 lm) [4, 5], hypertrophy secondary to
chronic valvular disease (20 ± 26 lm) [6], or DCM with-
out dialysis (25.6 lm) in our data. Myocyte disarray was
seen in 12 of our patients (30%). Although myocyte dis-
array is pathognomic, it is frequently observed in both hy-
pertrophic cardiomyopathy (HCM) and the dilated phase
of HCM [7, 8].
The other main finding was extensive fibrosis (22.3 ±
18.4%). Previous studies have shown that the LV fibro-
sis area is seen in 1.1% of the total area in the normal
heart, 2.6% in hypertensive heart disease, 10.5% in hyper-
trophic cardiomyopathy [9], 12.9% in DCM, and 35.8%
in the dilated phase of HCM [10]. This study shows the
similar extent of fibrosis between the DCM with dialy-
sis and DCM without dialysis. However, the percent area
of LV fibrosis varied widely in our subjects. Twelve pa-
tients (30%) in the dialysis group had an LV fibrosis area
of 0% to 10%; their pathologic characteristics did not
resemble the dilated phase of HCM, and their progno-
sis was far better than that of patients with severe fibro-
sis. The pathologic findings did not predict prognosis in
DCM patients without dialysis as shown in this study [11,
12], although other factors have reported to be predic-
tors, such as CTR, NYHA class, EF, peak oxygen con-
sumption, ventricular filling pattern, and ventricular ar-
rhythmia in DCM patients [11, 13–16]. In contrast, the
present study showed histologicaevidence of LV fibro-
sis predicted cardiac death in the dialysis patients with
DCM, even though CTR, EF, and NYHA class did not.
CTR, EF, and NYHA class could not represent the sta-
tus of heart failure because these factors are easily in-
fluenced by the adequacy of dialysis. Anemia and Ca-P
product are important predictors of mortality in diaysis
patients [17, 18]; nevertheless, LV fibrosis is the only in-
dependent predictor for cardiac death in this study. Also,
beta-blockers and ACE-I are not significant predictors in
this study, although these drugs have beneficial effects in
the patients with congestive heart disease [19–21]. How-
ever, there is no randomized trial to prove the efficacy
of ACE-I for dialysis patients. It is difficult to continue
to prescribe those drugs in dialysis patients because of
hypotension during hemodialysis and hyperkalemia. In-
deed, in this study, the use of angiotensin-converting en-
zyme inhibitors and/or angiotensin receptor antagonists
in the dialysis group was significantly lower than the con-
trol group in spite of the fact that the prevalence of hyper-
tension was significantly higher than the control group.
This study also highlights the poor prognosis of dial-
ysis group with severe fibrosis. The survival rate in the
control group was benign compared to previous reports
[22]. One of the reasons was that 48% of patients in the
control group were NYHA I/II classification. In addition,
the mean dialysis period was long (8.3 years) in the dial-
ysis group. Even if considering the benign survival rate
in the control group, the dialysis group with extensive fi-
brosis had a very poor prognosis and, in particular, the
3-year event-free survival rate for cardiac death with se-
vere fibrosis (above 30%) was only 42% compared to
82% in the dialysis group without severe fibrosis. We
used 30% by area of LV fibrosis as a cut-off point and
hypothesized that patients who have greater than 30% of
extent of LV fibrosis area constitute a high-risk group, as
the maximum fibrosis area of LV in patients with DCM
approximates 30% [10]. Intravascular volumes and LV
end-diastolic volumes (pressure) change frequently in pa-
tients on hemodialysis. Left ventricular fibrosis increases
LV compliance and results in diastolic dysfunction. As a
consequence, dialysis patients with a high extent of LV
fibrosis may represent a high-risk subgroup for the de-
velopment of congestive heart failure. Therefore, careful
follow-up and treatment are necessary for patients with
a high percent area of LV fibrosis.
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Fig. 5. Cumulative survival for cardiac death,
group stratified by the extent of fibrosis. Con-
tinuous bold line indicates the dialysis group
with an LV fibrosis area ≥30%. Dotted bold
line indicates the dialysis group with an LV
fibrosis area <30%. Continuous fine line in-
dicates the control group with an LV fibro-
sis area ≥30%. Dotted fine line indicates the
control group with an LV fibrosis area <30%
(P < 0.0001, not including the control group
with an LV fibrosis area ≥30%).
Endomyocardial biopsy is currently necessary to de-
tect these high-risk patients, although it is a highly in-
vasive method. It is currently impossible to distinguish
such patients with noninvasive methods like echocar-
diography, electrocardiography, or radiography. Doppler
echocardiography and tissue Doppler imaging can detect
diastolic dysfunction [23]. However, echocardiographic
diastolic markers such as E/A (early diastolic peak ve-
locity/late atrial diastolic peak velocity) and deceleration
time according to left ventricular inflow were unable to
distinguish the degree of left ventricular fibrosis in this
study. This may be because patients on dialysis have vari-
able hemodynamics, such as LV end-diastolic pressure.
Magnetic resonance imaging may be an important non-
invasive diagnostic tool to detect these high-risk patients
in the future if it could be utilized to quantitate LV fibrosis
[24, 25].
The limitations of this study are the small sample size
and the fact that the tissue examined was restricted to
subendocardial biopsy specimens of the left ventricle. The
information about the rest of the myocardium was not
obtained. However, the degree of fibrosis was not signifi-
cantly different between endovascular and subepicardial
regions, based on 2 cases from the dialysis group who
underwent autopsy in this study.
CONCLUSION
The pathologic characteristics of the heart in dialysis
patients with DCM are severe myocyte hypertrophy with
occasional disarray and a high percent area of fibrosis,
findings similar to those in the dilated phase of hyper-
trophic cardiomyopathy. The extent of LV fibrosis was a
strong predictor of cardiac death. Careful follow-up and
treatment are necessary for dialysis patients with a high
percent area of LV fibrosis.
Table 3. Multivariate analysis of the prognosis of cardiac death in the
dialysis group
Hazard ratio 95% CI P value
NYHA class III/IV 11.29 0.214–595.1 0.23
CTR ≥60% 3.941 0.254–61.25 0.33
Hypertension 0.220 0.022–2.183 0.20
Diabetes mellitus 0.727 0.010–50.45 0.88
Hemoglobin ≤9 g/dL 31.68 0.556–1807 0.09
Ca-P product ≥55 mg2/dL2 5.125 0.143–183.4 0.37
ACE-I/ARB 0.200 0.011–3.698 0.28
Beta blocker 9.135 0.736–113.4 0.08
EDVI ≥130 mL/m2 2.042 0.082–50.78 0.66
Ejection fraction ≤30% 6.856 0.350–134.3 0.20
Diameter of myocyte ≥40 lm 2.025 0.118–34.64 0.62
Percent area of LV fibrosis ≥30% 27.20 1.570–471.3 0.02
Abbreviations are: NYHA class, New York Heart Association functional
classification; CTR, cardiothoracic ratio; Ca, calcium; P, phosphorus; ACE-I,
angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor antagonist;
EDVI, left ventricular end-diastolic volume index; LV, left ventricle.
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